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Background: Japanese encephalitis virus (JEV) is the most important cause of epidemic encephalitis in most Asian
regions. There is no specific treatment available for Japanese encephalitis, and vaccination is the only effective way
to prevent JEV infection in humans and domestic animals. The purpose of this study is to establish a new mammalian
cell line stably and efficiently expressing virus-like particle of JEV for potential use of JEV subunit vaccine.
Results: We generated a new cell clone (BJ-ME cells) that stably produces a secreted form of Japanese encephalitis
virus (JEV) virus-like particle (VLP). The BJ-ME cells were engineered by transfecting BHK-21 cells with a code-optimized
cDNA encoding JEV prM and E protein expression plasmid. Cell line BJ-ME can stably produces a secreted form
of Japanese encephalitis virus virus-like particle (JEV-VLP) which contains the JEV envelope glycoprotein (E) and
membrane protein (M). The amount of JEV-VLP antigen released into the culture fluid of BJ-ME cells was as high as
15–20 μg/ml. JEV-VLP production was stable after multiple cell passages and 100% cell expression was maintained
without detectable cell fusion or apoptosis. Cell culture fluid containing the JEV-VLP antigen could be harvested five to
seven times continuously at intervals of 4–6 days while maintaining the culture. Mice immunized with the JEV-VLP
antigen with or without adjuvant developed high titers of neutralizing antibodies and 100% protection against lethal
JEV challenge.
Conclusion: These results suggest that the recombinant JEV-VLP antigen produced by the BJ-ME cell line is an
effective, safe and affordable subunit Japanese encephalitis vaccine candidate, especially for domestic animals
such as pig and horse.
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Japanese encephalitis virus (JEV) is the most important
cause of epidemic encephalitis in most Asian regions, with
about 35,000–50,000 cases of and 10,000 deaths from JEV
infection reported annually [1]. The virus can be found in
regions beyond its ecological boundaries, with recent re-
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unless otherwise stated.[2-4] and Pakistan [5]. Hence, there is concern that JEV
might become a global threat.
Japanese encephalitis (JE) caused by JEV is a mosquito-
borne zoonotic infectious disease [6,7]. A variety of ani-
mals are susceptible to JEV infection, but usually only
humans, horses and pigs with infection exhibit symptoms
[8-11]. Humans and horses are generally thought to be
dead-end JEV hosts [12,13]. Pigs are considered the most
important amplification and reservoir hosts of JEV in en-
demic regions [7,13]. JEV infection in pregnant sows can
cause abortion, stillbirth and other reproductive failure. In. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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flammation and hypospermia [14,15].
There is no specific treatment available for JE, and vac-
cination is the only effective way to prevent JEV infection
in humans and domestic animals. At present, there are
three kinds of JE vaccines available for humans: the live
attenuated virus vaccine SA14-14-2 [16-19], Vero cell-
derived formalin-inactivated whole-virus SA14-14-2 strain
vaccine IC51 and Beijing-1 strain vaccine JEBIKV [19-21],
and recombinant chimeric virus vaccine JE-CV [22,23].
These vaccines have better safety profiles and fewer side
effects compared with the mouse brain-derived inactivated
vaccine [24-26]. The attenuated live vaccine is derived
from primary hamster kidney cells, is difficult and costly
to manufacture, and the infectious agents are always asso-
ciated with potential biosafety issues.
The use of infectious agents is always a major issue with
manufacturing process of the currently used vaccines.
Therefore, the development of new types of JE vaccines
for humans and domestic animals that do not involve the
use of infectious JEV is imperative. Genetically engineered
vaccine is a potential new form of the JE vaccine. Previous
studies have shown that the pre-membrane (prM) and E
protein expressed in mammalian cells could assemble into
virus-like particles (VLP), and that the expressed JEV VLP
has the same ability to induce neutralizing antibodies and
protective efficiency as the JEV virion [27-30]. Thus, stud-
ies on second-generation JE vaccines have focused on the
production of the JEV-VLP antigen by genetic engineering
of a stable cell line. Different mammalian cell lines in-
cluding RK13 [31], COS-1 [32] and CHO-k1 [33] have
been used to construct stable cell lines that continuously
express JEV-VLP, but do not express efficiently or have
additional defects.
In this study, we have generated a new cell line, BJ-ME,
which can stably produce a secreted form of the JEV VLP
by using BHK-21 cells as the parent cell line. Mice immu-
nized with the expressed JEV-VLP antigen developed high
titres of neutralizing antibodies and complete protection
against lethal JEV challenges.
Results
Establishment of a stable cell clone continuously
expressing the prM/M-E antigen
From the cloned colonies of BHK-21 cells, 64 G418-re-
sistant and E protein-specific IFA-positive cell colonies
were picked and transferred to 24-well plates. After com-
parison of E protein expression in the culture medium of
the 64 cell colonies by Western blotting, 10 clones with
relatively high E protein expression were selected for fur-
ther comparison. After IFA testing and further cloning
purification, the E protein expression efficiency of all 10
cell clones was compared using E protein-specific Western
blotting. The clone of most efficiently expression E antigenwas selected and designated as BJ-ME (BHK-JEV-ME). The
cells were expanded and maintained in G418-containing
medium to observe JEV antigen production. The BJ-ME
cell clone had undistinguishable morphology from paren-
tal BHK-21 cells and induced no polykaryocyte formation.
When the fifth-passage BJ-ME cells were examined by in-
direct immunofluorescence and flow cytometry, over 94%
of BJ-ME cells were positively stained with JEV E protein-
specific MAb 5E7. This high percentage of E-expressing
cells was maintained till the twentieth passage (Figure 1).
Western blotting results with the MAbs 5E7 and 3C8
showed that BJ-ME cells expressed the prM and E pro-
tein together, and the majority of prM in the cells did
not show cleavage. When secreted into culture medium,
most of the prM protein was cleaved by furin into ma-
ture M protein (Figure 2).
The morphology of BJ-ME cells was further examined by
transmission electron microscopy. The results showed that
VLP structure was observed in the endoplasmic reticulum
of cells (Figure 3A,B), and this JEV-VLP structure was fur-
ther confirmed with purified JEV-VLP by negative staining
electron microscopy observation (Figure 3C). The ap-
pearance of the JEV-VLP was in the form of particles
with an average diameter of 40–50 nm surrounded by a
lipid bilayer.
Passage stability and antigen expression of BJ-ME cells
For BJ-ME cells, passage 1 was defined as the cell culture
from the 96-well plate by limiting dilution cloning and with
100% E expression. After expansion and cryopreservation,
the culture medium of BJ-ME cells cultured in 75 cm2
flasks was collected from passage 5. The JEV-VLP was puri-
fied by ultrafiltration and rate zonal centrifugation. The
purified antigen was used in negative staining electron mi-
croscopy observation and used as the antigen standard in
an antigen capture ELISA quantification assay.
To evaluate the antigen expression dynamics of BJ-ME
cells, the confluent BJ-ME cells were passaged 1:5 into
75 cm2 flasks with 20 ml medium containing 10% FBS.
For antigen amounts detection, in next day, the cells
started growing in confluence and the medium contain-
ing 10% FBS were changed into maintaining medium
(containing 1% FBS). Twenty four hours later, 600 μl of
the culture medium was replaced with fresh serum-free
medium every day. The amount of JEV-VLP was deter-
mined by ELISA. As shown in Figure 4A, the amount of
JEV-VLP in the culture medium kept increasing in the
first four days. From the fifth day, it reached a plateau,
after which it started showing a slight increase from the
fifth to tenth day. Cell culture fluid containing the JEV-
VLP antigen could be harvested five to seven times con-
tinuously at intervals of 4 to 6 days during culture, and
the concentration of JEV-VLP antigen collected at each
harvest was over 15 μg/ml (Figure 4B).
Figure 1 Immunofluorescence and flow cytometry analysis of BJ-ME in the 5th and 20th generation with monoclonal antibody against
the JEV E protein. The percentages of cells expressing E protein in the 5th and 20th generation of BJ-ME cells were all over 94%.
Figure 2 Cell lysates and culture supernatants were analyzed by
Western blotting with MAbs (5E7 and 3C8). 1, Cell lysates of BJ-ME
cells; 2 and 3, Culture supernatants of BJ-ME cells. 4, JEV control. 5, Cell
lysates of BHK-21 cells. Relative locations of E, prM and M protein of
JEV were indicated on the right.
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cells was further evaluated using cryopreserved cells.
After thawing, BJ-ME cells were passaged every 2 days
in 75 cm2 flasks. For antigen testing, the culture medium
of confluent cells were changed into fresh maintaining
medium. 4 to 5 days later the culture medium was
collected at the 5th, 10th, 15th, and 20th passages and
examined for the amount of JEV-VLP antigen by ELISA
(Figure 4C). Although the amount of JEV-VLP antigen
produced by BJ-ME cells differed little between passages,
more than 15 μg/ml of the JEV-VLP antigen was detect-
able throughout the monitoring period. Even at the 20th
passage, the frequency of E-expressing cells was over
94% (Figure 1).
Immunogenicity and protective efficacy of the JEV-VLP
Mice administered the JEV-VLP with or without adju-
vant developed high titers of neutralizing antibody. Even
the neutralizing antibody titer in mice that were not ad-
ministered the adjuvant was somewhat higher than that
observed in mice immunized with the live virus vaccine
(Table 1). All mice immunized with the JEV-VLP with or
without adjuvant and the live virus vaccine were completely
protected against JEV. All mice that were administered
PBS died within 10 days after the challenge (Figure 5A).
For the second experiment, the immunogenicity and
protective efficacy of different doses of the antigen were
evaluated. As shown in Table 1, mice in the groups ad-
ministered 3 μg and 2 μg of the antigen developed high
levels of neutralizing antibody similar to that of the live vac-
cine group and were completely protected against the JEV
challenge. Mice in the groups administered 0.3–1.5 μg of
the antigen developed relatively lower titers of neutralizing
Figure 3 Electron micrographs of BJ-ME expression of JEV VLP. (A) Low-magnification image of BJ-ME cells. (B) Higher magnification image
of BJ-ME cells. Virus-like particles in the ER of BJ-ME cells are indicated with arrowheads. (C) JEV VLP purified from the culture supernatant of
BJ-ME cells. The purified antigen was processed for negative staining and observed with an electron microscope.
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the survival rate in all groups was higher than 70% (Table 1,
Figure 5B).
Discussion
There is an urgent need for an effective, affordable and safer
JE vaccine for humans and domestic animals. Biotechnically-
engineered cell lines expressing the JEV-VLP antigen may
meet this requirement. Here, we describe another alterna-
tive, a recombinant subunit vaccine candidate, based on a
new mammalian cell line.
The BJ-ME cells described in this study produce ex-
tremely high levels of the JEV-VLP antigen—15–20 μg/
ml—which is higher than that of any other reported cell
lines such as J12#26 [31], F [33] and JE-4B [32]. This
value was determined under experimental conditions in-
volving simple changes in the culture medium, and we be-
lieve that the titer could be further increased under
optimal culture conditions. Moreover, time-course results
suggest that 5 days of incubation is sufficient for antigen
production.
BJ-ME cells had similar cell morphology and growth
characteristics as the parental BHK-21 cells. In fact, cell
clones with different morphogenetic characteristics found
during the selection and cloning process were found to re-
lease the E antigen inefficiently. This phenomenon indi-
cates that maintaining similar morphology and growth
characteristics with the parental cells may be important in
the engineering of cell lines with high efficiency and stable
exogenous gene expression. Another factor that may have
contributed to the high efficiency of JEV-VLP antigen ex-
pression in BJ-ME cells is the genetic codon optimization
of the cDNA sequence encoding the prM and E proteins.
Different species have codon usage bias, and optimizing
the genetic codon according to the bias of the expressing
host could increase the expression efficiency of the target
gene [34-36]. The BJ-ME cells showed stable JEV-VLP
production during cell culture and passage. Even after 20–25 passages, the JEV-VLP antigen-producing efficiency of
BJ-ME cells was not significantly reduced.
A major obstacle to the stable expression of flavivirus
membrane protein in mammalian cells is its cytotoxicity.
In a previous report, attempts to establish cells with high
expression of the prM-E protein from Vero cells were
unsuccessful [31]. This is probably because Vero cells
are susceptible to JEV infection, which makes them sen-
sitive to the cytotoxic effects of the JEV-VLP antigen. Al-
though BHK-21 cells are susceptible to JEV infection, we
did not observe any obvious cytotoxic effects of JEV
VLP. It was possible to obtain dozens of G418-resistant
cell colonies with a single transfection and selection
cycle. The cell line BJ-ME constructed in this study has
the same growth characteristics as the parent cell line
BHK-21. So this cell line could easily be cultured in
serum-free or low-serum medium. J12#26 cells derived
from RK13, a rabbit kidney cell line, was the most stable
and highest antigen-producing cell line in all previous
reports [31]. However, RK13 cells grow slowly and could
not reach high cell density, so are not suitable for large-
scale culture. Another important point is that RK13 cells
contain bovine viral diarrhea virus [37], which make
them unsuitable for vaccine antigen production.
To overcome the fusogenic cytotoxicity of JEV prM-E
protein expression in mammalian cell lines, Konishi et al.
[33] introduced a mutation at the prM/M cleavage site to
prevent authentic processing and to reduce the toxic
fusion activity of the expressed VLP, and established an
F-cell line using CHO-k1 as the parent cell line. The elim-
ination of cleavage of the prM protein resulted in the pro-
duction of immature VLPs, which are quite different in
their conformational structure from the mature VLPs pro-
duced by authentic cleavage of prM [38]. These structural
differences may eliminate virus conformational neutraliz-
ing epitopes. Moreover, reports have shown that most
JEV-neutralizing epitopes are conformation dependent
[39]. The differences in the conformational structure will
Figure 4 Production of the JEV-VLP antigen by BJ-ME cells.
(A) Confluent BJ-ME cells were incubated with the maintaining
medium for 10 days. The amount of JEV-VLP antigen produced each
day (24 h) was determined by ELISA. (B) The culture medium of
confluent BJ-ME cells was refreshed every 4 to 6 days continuously,
and the amount of JEV-VLP antigen in culture supernatants harvested
multiple times was determined by ELISA. (C) Effect of long-term
passage on production of JEV-VLP antigen by BJ-ME cells. BJ-ME
cells were passaged every 3 days in a 75 cm2 flask, and the
amount of antigen produced by BJ-ME cells from the different
passages was analyzed using ELISA.
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protection rate in mice immunized with the F antigen
with uncleaved prM protein did not exceed 50% [33]. Re-
cently Yamaji et al. further reported expressing the JEV
prM protein mutated virus-like particles with baculovirus
[40] and lepidopteran insect cell lines [41]. Obviously the
yield of E antigen were increased in both of two express-
ing systems, especially the E antigen yield reached about
30 μg/ml in lepidopteran insect cell line. However, thesestudies did not present immune protection result of these
immature JEV virus-like particles with uncleaved prM
protein. The differences in structural and immune pro-
tective effect between immature and mature JEV virus-like
particles need further evaluation. Maybe DENV-related
reports [42,43] could provide some clues for future survey
the relation of immune protective effect and structure of
virus-like particles.
As expected be of particulate form, the BJ-ME antigen
was immunogenic. With or without adjuvant, dose of
2 μg of BJ-ME induced high titers of neutralizing anti-
bodies and provided complete protection against chal-
lenge. However we observed no enhancement effect of
the adjuvant in this experiment which may because the
antigen amount of 2 μg is overdosed for mice. Another
experiment with different dose of antigen showed that
0.3 μg of BJ-ME antigen could induce effective protec-
tion neutralizing antibodies titer of 1:40 which is higher
than surrogate maker for seroprotection of neutralizing
antibody titer of 1:10.
Conclusions
The new established cell line BJ-ME could efficiently
and stably produces secreted form of JEV-VLP. BJ-ME
cells expressing the JEV-VLP antigen showed good im-
munogenicity in mice. An antigen dose of at least 0.3 μg
could induce neutralizing antibody production, and
more than 70% of immunized mice survived after lethal
challenge with JEV. These results suggest that the re-
combinant JEV virus-like particle antigen produced by
the BJ-ME cell clone is an effective, easy to produce,
and safe second-generation subunit JE veterinary vac-
cine candidate. Moreover, the JEV-VLP could be used
to make diagnostic reagents for JE and JEV.
Methods
Animal ethics
Care of laboratory animals and animal experimentation
were performed in accordance with animal ethics guide-
lines and approved protocols. All animal experiments
were approved by the Animal Ethics Committee of Harbin
Veterinary Research Institute of the Chinese Academy of
Agricultural Sciences. The Animal Ethics Committee ap-
proval number was SYXK (Hei) 2011–022.
Cells and viruses
Baby hamster kidney BHK-21 cells (CCL-10; ATCC) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (FBS; Gibco, Grand Island, NY). C6/36
cells (CRL-1660; ATCC) were cultured at 28°C in a 5%
CO2 atmosphere in RPMI-1640 (Gibco, Grand Island,
NY) supplemented with 10% FBS. The attenuated JEV
vaccine strain SA14-14-2 was propagated and titrated on
Table 1 Induction of neutralizing antibodies in mice vaccinated with the JEV-VLP antigen
Expt Vaccine Dosage Neutralizing antibody titera Survival rate
(no. alive/total)Day 14 Day 28
1 BJ-MEb (oil adjuvant) 2 μg 40 100 100% (10/10)
BJ-ME (no adjuvant) 2 μg 70 100 100% (10/10)
BJ-ME (no adjuvant) 4 μg 100 280 100% (10/10)
Live vacc 106 TCID50 100 120 100% (10/10)
PBS 200 μL <10 <10 0% (0/10)
2 BJ-ME 200 μl 3 μg ND 160 100% (8/8)
BJ-ME 150 μl 2.25 μg ND 140 100% (8/8)
BJ-ME 100 μl 1.5 μg ND 100 87.5% (7/8)
BJ-ME 50 μl 0.75 μg ND 70 87.5% (7/8)
BJ-ME 20 μl 0.3 μg ND 40 75% (6/8)
Live vac 106 TCID50 ND 160 100% (8/8)
PBS 200 μL ND <10 0% (0/8)
aTiters are expressed as the maximum serum dilution yielding a 50% plaque reduction. bJEV-VLP antigen. cLive virus vaccine (SA14-14-2 strain). ND, not determined.
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The P3 strain of JEV used to challenge mice was propa-
gated in mouse brains. The P3 strain of JEV used in the
plaque reduction neutralizing assay was passaged through
C6/36 cells twice, and then passaged twice through BHK-
21 cells.
Construction of plasmids carrying the prM and E genes of
JEV
First, a genetic codon-optimized JEV cDNA encoding
the viral signal peptide of the carboxyl terminus of the
C, prM, and E protein of the SA14-14-2 strain (amino
acid positions 106 to 794, GenBank: AAK11279.1) was
synthesized and cloned into the pUC57 plasmid. Then
DNA fragment was subcloned into the the expression
vector pCAGneo to generate pCAGneo-opti-JEV-ME.
The plasmid pCAGneo contains the neomycin resistance
gene, which confers resistance to G418. The resultingFigure 5 Protection of mice against challenge with JEV. (A) Groups of
Immunized mice in all groups of JEV-VLP with or without adjuvant survived in
All mice were challenged with 1.0 × 107 PFU of the P3 strain of JEV.plasmid pCAGneo-opti-JEV-ME was used to transfect
stable cell lines.
Establishment of stable cell lines constitutively producing
the E antigen
Monolayer or subconfluent BHK-21 cells were trans-
fected with the pCAGneo-opti-JEV-ME plasmid using
FuGENE HD transfection reagent (Roche Diagnostic
GmbH, Mannheim, Germany). Two days later, the trans-
fected cells were digested and cloned by limited dilution
in 96-well plates and growth in medium containing G418
(1000 μg/ml). The cloned cells were selected by Indirect
immunofluorescence assay (IFA) with JEV E protein-
specific monoclonal antibody 5E7 (unpublished data). The
amount of E antigen in culture supernatants from cloned
cells was examined and compared by Western blotting.
One clone designated BJ-ME (BHK-JEV-ME) that showed
obviously more efficient expression of the E antigen was10 4-week-old BALb/c mice were vaccinated as in Table 1 experiment 1.
100%. (B) Survival rate of different dosage of JEV-VLP immunized mice.
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antigen production.
Indirect immunofluorescence assays and flow cytometry
analysis
The cells were washed with phosphate-buffered saline
(PBS), fixed with 4% paraformaldehyde at room temperature
for 20 min, washed and then premeabilized with PBS
containing 0.1% Triton X-100 (PBS-T). Then the cells
were probed with JEV E protein-specific MAb 5E7 or
JEV prM/M protein-specific MAb 3C8 at the procedure
described before [44]. And cell nuclei were stained with
DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride).
Cells were then observed under a fluorescence microscope
(IMT2 Olympus, Tokyo, Japan). For flow cytometry ana-
lysis, the cells were dispersed by trypsin digestion and
then fixed as above described.
Antigen purification
The culture medium collected at 4–6 days after subcul-
ture of BJ-ME cells was clarified by centrifugation. The
clarified medium was concentrated 40-fold in volume by
ultrafiltration with a membrane with a size exclusion limit
of 100 kDa (Biomax100; Millipore, Bedford, MA, USA).
The concentrate was subjected to rate zonal centrifugation
in 10–50% (wt/wt) linear sucrose gradients. Fractions were
collected and analyzed by SDS-PAGE and Western blot-
ting for the E antigen. Fractions of 20–30% sucrose were
collected and pooled. Sucrose was removed from the E
antigen pool by Sephadex G-25 chromatography with the
NAP-25 column (GE, Westborough, MA, USA), equili-
brated and eluted with PBS. The purified JEV-VLP in PBS
was quantified with quick-start Bradford protein assay kits
(Bio-Rad Laboratories Inc., Hercules, CA, USA) according
to the manufacturer’s instructions.
Western blotting analysis
JEV-VLP antigen in BJ-ME cell culture supernatants or
cell lysates were analyzed by Western blot analysis at the
procedure described previously [44]. The membrane was
probed with MAb 5E7 or/and 3C8.
Antigen capture ELISA for quantification of antigen
The amounts of the BJ-ME antigen were quantified by a
sandwich ELISA with a pair of JEV specific MAb. 5E7
and 5B10 which were generated with purified BJ-ME
antigen according to the procedure described previously
[44-46]. Briefly MAb 5B10 (2 μg/ml) was coated on 96-
well plates overnight at 4°C, and blocked with 5% skimmed
dried milk for 2 h at 37°C. Subsequently, the plates were
washed three times with phosphate-buffered saline with
0.1% Tween-20 (PBST). In the binding assay, the plates
were incubated with the various dilutions of samples at
37°C for 2 h followed by washing three times with PBST.Bound antigens were detected with horseradish peroxid-
ase (HRP)-conjugated MAb 5E7. After additional incuba-
tion 37°C for 1 h and thorough washing with PBST,
the reactions were developed with TMB substrate. The
reaction was stopped with 2 M H2SO4, and absorbance
was measured at 450 nm using a microplate autoreader
(Bio-Rad, Hercules, CA, USA). The results are presented
as the average of duplicate assays. A stock of purified
BJ-ME antigen was serially twofold diluted and used as
standards. The antigen amounts of each sample were de-
termined from the standard curve.
Electron microscopic observation
Virus-like particles in BJ-ME cells were examined with
transmission electron microscope as reported procedure
[31]. For observation of BJ-ME cells expressing VLP in the
culture supernate, the purified JEV-VLP was processed for
negative staining on copper formvar-coated grids. Speci-
mens were stained with sodium phosphotungstate and ob-
served under an electron microscope.
Immunization and challenge of mice
The supernates of BJ-ME cells cultured for 6 days without
FBS were harvested and used for immunization. Super-
nates containing 20 μg/ml antigen emulsified with the
same volume of MONTANIDE ISA50V2 (SEPPIC S.A.,
Paris, France) were used for immunization with a 200 μl
dose to each mouse. Other two groups of 4-week-old fe-
male BALB/c mice were immunized subcutaneously with
a 200 μl (for 4 μg antigen without adjuvant group) and
100 μl (for 2 μg antigen without adjuvant group) dose
given to each mouse. PBS and 106.5 TCID50/0.2 ml of the
attenuated JEV vaccine strain SA14-14-2 given at the same
dose were used as the negative and positive control, re-
spectively. Two weeks after the first immunization, an en-
hanced immunization was given. Except for only once
immunization was given for the live virus vaccine group.
Mice were bled at intervals of 2 weeks for up to 4 weeks
after the first immunization. Pooled serum samples from
each group were stored for virus neutralizing antibody
testing. Mice were challenged with intraperitoneal injec-
tions at the day after the last bleed with a 1.0 × 107 PFU of
the P3 strain of JEV and observed for 2 weeks.
In another experiment, the supernates containing differ-
ent amount of antigen (0.3 μg to 3 μg per mouse) without
adjuvant were used as immunogen. Groups of eight 4-
week-old BALB/c mice were immunized, bled and chal-
lenged as described above. PBS and the live virus vaccine
control groups were also conducted as described above.
Neutralizing antibody testing
Virus neutralizing antibodies present in the mouse and
pig sera were tested using a plaque reduction assay [31].
Except that BHK-21 cells were used rather than Vero
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reciprocal of the serum dilution yielding a 50% reduction
in the mean plaque number versus that in the control
wells.
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